Thrombolex, Inc.
PrivateLast Round
Series A
Mar 12, 2026
Total Funding Raised
$13.82M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Thrombolex, Inc. operates in Healthcare & Life Sciences and is based in New Britain, Pennsylvania. Its latest recorded funding round was a VC Round in August 2022.
Thrombolex, Inc. is a medical device company that designs, develops, and distributes innovative endovascular catheters used in interventional procedures for patients who suffer from arterial and venous thromboembolic conditions.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Thrombolex, Inc. Comparables
Compare Thrombolex, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SonoVascular, Inc. | 92% | |
| Innova Vascular | 88% | |
| Caeli Vascular, Inc. | 86% |
For institutional investors. Book with your work email.
Thrombolex, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 12, 2026 | ||||
| Series B | Jun 4, 2024 | ||||
| VC Round | Aug 30, 2022 | ||||
| VC Round | Nov 29, 2021 | ||||
| Grant | Jul 5, 2020 | ||||
Series A | Feb 3, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Thrombolex, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OrbiMed | Series A |
| National Heart, Lung, and Blood Institute | Grant |
| Delaware Crossing Investor Group | VC Round, Series A |
| National Heart, Lung, and Blood Institute | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 4, 2026
Grew 24% QoQ, from 25 to 31 employees.
- Jul 15, 2026
Grew 47% QoQ, from 17 to 25 employees.
For institutional investors. Book with your work email.
Thrombolex, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Thrombolex, Inc.'s valuation, stock price, and market status.
Is Thrombolex, Inc. a public or private company?
Thrombolex, Inc. is a private company.
What is the current stock price of Thrombolex, Inc.?
Thrombolex, Inc. is a private company, so its shares have no public market price. Caplight tracks Thrombolex, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Thrombolex, Inc. worth (valuation)?
Valuation information for Thrombolex, Inc. is not publicly available.
Can I buy Thrombolex, Inc. stock?
Thrombolex, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Thrombolex, Inc.'s last funding round?
Thrombolex, Inc.'s most recent funding round was Series A on March 12, 2026.
Who are the main investors in Thrombolex, Inc.?
Key investors in Thrombolex, Inc. include OrbiMed.
Will Thrombolex, Inc. IPO soon?
No public IPO plans have been announced for Thrombolex, Inc..
How can I track Thrombolex, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Thrombolex, Inc.'s shares on secondary markets.